

DONCASTER & BASSETLAW AREA PRESCRIBING COMMITTEE (APC)

Action Notes and Log

Thursday 31st January 2019 12 Noon start,
Meeting Room 3 Sovereign House

Present :	Dr David Crichton Mr Alex Molyneux Dr Rachel Sykes Mr Rob Wise Mr Stephen Davies Dr Rमित Shah Mrs Rachel Wilson	NHSD Chair, APC Chair NHSD Head of Medicines Management NHSD GP NHS Bassetlaw Head of Medicines Management, Deputy APC Chair Chief Pharmacist RDaSHFT Local Medical Committee Representative Deputy Chief Pharmacist DBTHFT
In attendance :	Mrs Angie Machin	NHSD Medicines Management Technician
Minutes only :	Dr Mark Pickering Dr Rupert Suckling & Victor Joseph	Doncaster Offender Health, Chair Prisons D&T Committee DMBC Representatives

--

Agenda Ref	Subject / Action Required	Action Required By	Timescale	Status of Action (RAG) and Date
01/19/1	Apologies for Absence : Mr. J Bane, Dr L Peart, Mr L Wilson			
01/19/2	Declarations of Interest : None declared			
01/19/2.1	Fire Alarm Procedure			
01/19/2.2	Notification of Any Other Business ICS SCP Template			
0119/3	Notes of the Meeting Held On : Thursday 29 th November 2018 were agreed as a true and accurate record and will be made available on the medicines management website			
01/19/4	Matters Arising not on the Agenda			
01/19/4.1	Matters Arising			
10/17/8.1	<p>FreeStyle Libre (FSL) Glucose Monitoring System</p> <p>The committee was given an update regarding the funding situation of FSL including:</p> <ul style="list-style-type: none"> • A payment system has been agreed for patients seen in Rotherham and Sheffield. This will be in place until the end of this financial year, PbR excluded payments will then be in place. • Quality and Contracting meeting will agree the funding arrangement for RDaSHFT <p>In Doncaster Primary Care should see requests for FP10 prescribing from June 2019 with the exception of a small number of children seen in Sheffield, Primary Care will not be required to provide any monitoring of these patients.</p> <p>In Bassetlaw there has been agreement to follow arrangements in place at the places of initiation.</p>			

06/18/8.1	Bicalutamide: Amber G (current status) vs Amber The SCP was approved for use, the TLS status will change from Amber G to Amber. The paperwork will be available on the medicines management website and will be sent to DBTHFT for their use going forward.			
10/18/19.1	Dalteparin- supply issue DBTHFT confirmed that other than the 2500IU stock levels are now good. The committee agreed that this should not cause any major problems and were advised that the 2500IU dose is due in stock imminently.			
11/18/8.1	Sodium oxybate for adults –TLS status The committee was updated on the current situation locally. Sheffield – obtained via the IFR route Barnsley – the drug is non-formulary Rotherham – the drug is not listed The committee was in agreement that sodium oxybate should remain Red on the TLS and it was agreed that Sheffield would be advised of this position.	NHSD AJM		
11/18/8.2	Licensed Hydrocortisone granules Deferred to the February meeting	DBTHFT-LW		
11/18/8.4	RMOC Liothyronine prescribing guidance The committee discussed the data collection done in Doncaster Primary Care, 13 patients were identified as receiving liothyronine of which 6 patients were not under the care of a NHS endocrinologist. It was agreed that NHSD-MMT would identify these patients to Primary Care and ask that they are referred into Secondary Care for review. The TLS status for liothyronine will be: Amber-G for hypothyroidism Red for depression and oncology reasons BCCG estimated that there were 5 patients receiving liothyronine, NHSB-MMT will highlight this to Primary Care	NHSD AJM NHSD RW		

11/18/8.5	Cinacalcet for complex primary hyperparathyroidism in adults Further consideration has been given to the TLS status by DBTHFT and due to the low amount of prescribing it has been agreed to keep the prescribing in Secondary Care therefore the status remains Red.	NHSD AM		
01/19/5	Drugs for Review Padeliporfin (TOOKAD) used to treat prostate cancer has been categorised as Grey 1(Evidence available supports that use in this area is inappropriate) Doxylamine/ Pyridoxine (Xonvea) used in nausea and vomiting in pregnant women. Further research of local decisions will be conducted and a further discussion will take place at the February meeting. Vandetanib (Caprelsa, Zactima) used to treat thyroid cancer has been categorised as Grey 1(Evidence available supports that use in this area is inappropriate) Darvadstrocel (Alofisel) used to treat perianal fistulas has been categorised as Grey 1(Evidence available supports that use in this area is inappropriate)	NHSD AM		
01/19/6	Officers action All officers actions were agreed as proposed and will be updated on the traffic light system	NHSD AM		
01/19/7	Drugs for Consideration Brigatinib (Alunbrig) used to treat Anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer has been categorised as Red 1,2,3 Doravirine (Pifeltro) and Doravirine/lamivudine, tenofovir disoproxil fumarate (Delstrigo) used to treat HIV has been categorised as Red 1,2 Oral nutritional supplements have been categorised as Amber-G (Doncaster only) Adrenaline auto injectors have ben categorised as Green-G Semaglutide (Ozempic) used to treat type 2 diabetes has been categorised as Grey-4 further advice sought from FLG Burosumab (Crysvida) used in Hypophosphataemia has been categorised as Red 1,2 Ertugliflozin (Steglatro) used to treat type 2 diabetes has been categorised as has been categorised as Grey-4 further advice sought from FLG	NHSD AM		

	Lanadelumab (Takhzyro) used in hereditary angioedema has been categorised as Red 1,2,3			
01/19/8	New Business			
01/19/8.1	Hydroxychloroquine guidance The committee was asked to confirm that the Doncaster and Bassetlaw SCP paperwork reflected the updated Sheffield paperwork. This was confirmed and therefore no further changes are needed to the current document.			
01/19/8.2	Unlicensed cannabis guidance statement The latest Prescqiip guidance document was presented to the committee for information.			
01/19/8.3	Epilepsy Guidance for children The committee discussed the Sheffield Epilepsy Guidance for children document and considered that suggestions made at this committee had not been fully captured. NHSB-MMT agreed to feed this back to Sheffield. The committee agreed that the flowchart used in the adult guidance document could be added as an appendix to the website once the children's guidance has been approved.	NHSB-RW NHSD AM		
01/19/8.4	Sacubitril/Valsartan Amber-G The current guidance document is due for routine review. The committee agreed that the document is still appropriate and as such the review date will be updated and the new document will be added to the medicines management website.	NHSD AM		
01/19/8.5	Palliative Care Guidance The committee has been asked to consider the placing of the palliative care guidance document on the medicines management website. At present this suite of documents can be found on the 'guidance' section of the website. The committee was in agreement to the documents remaining in this section of the website and will promote this via the medicines management newsletter (The T@blet)	NHSD AJM		

01/19/8.6	<p>Avastin</p> <p>The committee was given an update on the ICS current position looking at:</p> <ul style="list-style-type: none"> • Issues around licencing • Safety and efficacy • Number of out- patient appointments required for patients on avastin in comparison to other preparations 	NHSD AJM		
01/19/8.7	<p>ToR and the flowchart to support the management of shared care prescribing arrangements</p> <p>The ToR has been updated to give Bassetlaw a more equitable presence and also to reflect recent changes in the APC membership.</p> <p>The updated flowchart was also discussed and following minor changes was agreed.</p> <p>Dr Shah (LMC) highlighted that there was an agreement limiting the number of new SCP to be introduced per year. The committee was reminded that the APC annual report documents all new work-streams as an audit of this.</p>	NHSD AJM		
01/19/8.8	<p>Heel balm TLS</p> <p>The committee was advised of several requests received from the podiatry department for Primary Care to prescribe high priced branded products. An example being Eucerin for the treatment of cracked skin on the feet. There was a suggestion to add such items to the TLS system to support Primary Care to remain within formulary choices. NHSD-MMT will await further information from podiatry and feedback at the next meeting</p>	NHSD AJM		
01/19/8.9	<p>Blood Glucose meters, test strips, lancets and needles</p> <p>The updated guidance document was received by the committee for information purposes.</p>			
01/19/8.10	<p>Alzheimer's disease and non-Alzheimer's Dementia SCP</p> <p>The committee discussed the content of the updated paperwork and agreed with its content. RDaSHFT agreed to format it and send it on to NHSD Medicines Management Group for consideration. The documents will return to this</p>	RDaSHFT SD		

	committee for final approval.			
01/19/9	DBTHFT D&TC Update The minutes of the meeting held in November 2018 were received by the Committee			
01/19/10	Formulary Liaison Group Update No minutes available			
01/19/11	Doncaster Prisons Drug & Therapeutic Committee update No minutes available			
01/19/12	RDASH FT Medicines Management Committee update The minutes of the meeting held in November 2018 were received by the Committee			
01/19/13	Barnsley Area Prescribing Committee Update The minutes of the meeting held in October 2018 were received by the Committee			
01/19/14	Rotherham Medicines Optimisation Group Update The minutes of the meeting held in September, October and November 2018 were received by the Committee			
01/19/15	Sheffield Area Prescribing Committee Update The minutes of the meeting held in October 2018 were received by the Committee			
01/19/16	Nottingham Area Prescribing Committee Update The minutes of the meeting held in Septemberr 2018 were received by the Committee			
01/19/17	SY& B sICS Medicines Optimisation Work-stream Steering Group No minutes available			
01/19/18	Northern Regional Medicines Optimisation Committee No minutes available			
01/19/19	Any Other Business 01/19/19.1 Guidelines for the management of children with suspected Vitamin D deficiency This document was received by the committee it will be available on the medicines management website 01/19/19.2			

	<p>ICS Shared Care Protocol Template This template was formally approved by the committee. As SCP's come up for review the content of existing paperwork will be transferred over to this format.</p> <p>01/19/19.3 The Chair gave his apologies for the next meeting. Mr R Wise will chair the meeting.</p>			
	<p>01/19/19.3 The Committee was asked if there was any guidance to support Primary Care when monitoring for vitamin deficiency following bariatric surgery. DBTHFT agreed to make enquiries and feedback at the next meeting.</p>	DBTHFT		
01/19/19.1	<p>Date and Time of Next Meeting</p> <p>12 noon prompt Thursday 28th February 2019 in Meeting Room 3 Sovereign House</p>			
	<p>12 noon prompt Thursday 28th March 2019 in Meeting Room 3 Sovereign House</p> <p>12 noon prompt Thursday 25th April 2019 in Meeting Room 3 Sovereign House</p> <p>12 noon prompt Thursday 30th May 2019 in Meeting Room 3 Sovereign House</p> <p>12 noon prompt Thursday 27th June 2019 in Meeting Room 3 Sovereign House</p> <p>12 noon prompt Thursday 25th July 2019 in Meeting Room 3 Sovereign House</p> <p>12 noon prompt Thursday 29th August 2019 in Meeting Room 3 Sovereign House</p>			

KEY

Completed / Closed	To Action
In Progress	To be actioned but date not yet due